RACHEL SCHIFF to Estrogen Receptor alpha
This is a "connection" page, showing publications RACHEL SCHIFF has written about Estrogen Receptor alpha.
Connection Strength
3.594
-
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology. 2022 01 01; 163(1).
Score: 0.610
-
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017 May; 19(5):35.
Score: 0.441
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.424
-
ESR1 mutations?a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015 Oct; 12(10):573-83.
Score: 0.389
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.236
-
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008 Apr; 29(2):217-33.
Score: 0.232
-
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11.
Score: 0.195
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
Score: 0.154
-
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020 08 08; 22(1):84.
Score: 0.138
-
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERa-GREB1 Transcriptional Axis. Cancer Res. 2018 02 01; 78(3):671-684.
Score: 0.115
-
Identification of MYST3 as a novel epigenetic activator of ERa frequently amplified in breast cancer. Oncogene. 2017 05 18; 36(20):2910-2918.
Score: 0.107
-
Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nat Commun. 2016 10 03; 7:12991.
Score: 0.106
-
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
Score: 0.091
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.090
-
Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res. 2012 Jan 01; 18(1):118-26.
Score: 0.075
-
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
Score: 0.061
-
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
Score: 0.036
-
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nat Cell Biol. 2020 06; 22(6):701-715.
Score: 0.034
-
Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nat Commun. 2019 04 03; 10(1):1522.
Score: 0.032
-
Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010 Aug; 30(15):3827-41.
Score: 0.017
-
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9.
Score: 0.010